In non-small cell lung cancer (NSCLC) and melanoma, Axl inhibitors have been paired with checkpoint blockade therapies (e.g., anti–PD-1 or anti–PD-L1), which can convert immune-excluded tumors into inflamed, T cell–infiltrated environments (125). This evidence concerns the gene AXL and non-small cell lung carcinoma.